After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals ...

CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and core operating income rising 29% in constant currency. For the full year, the company achieved a ...

Novartis CEO Vas Narasimhan has expressed concern over the United States' withdrawal from the World Health Organization, highlighting potential impacts on global health initiatives. These programmes, ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

Novartis CEO Vas Narasimhan weighs in on the impact of the new U.S. administration and artificial intelligence on the ...

Moves by the incoming Trump Administration may be a boon to drugmakers, Novartis AG Chief Executive Officer Vas Narasimhan said, while concerns over vaccine policies and public health funding are ...

Novartis CEO Vas Narasimhan outlined projections for the company's future at the 2025 JP Morgan Healthcare conference in San Francisco on 14 January. Novartis, he said, expects peak sales of over ...